Feng Huang,
Lei Song 
For correspondence:- Lei Song Email: songleisl1@hotmail.com Tel:+865398226999
Received: 3 March 2017 Accepted: 26 May 2017 Published: 29 June 2017
Citation: Huang F, Song L. Nanoemulsion formulation of Abatacept for lupus nephritis therapy. Trop J Pharm Res 2017; 16(6):1205-1213 doi: 10.4314/tjpr.v16i6.1
© 2017 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To formulate a nanoemulsion preparation of abatacept and evaluate its treatment efficacy in a C57BL/6 J mouse model of lupus nephritis (LN).
Methods: An abatacept nanoemulsion formulation was prepared using coarse homogenization followed by high-energy ultrasonication. The formulation was assessed for particle size and charge, morphology, and stability. C57BL/6 J mice treated with pristane (to create a mouse model of LN) received subcutaneous injections of the abatacept formulation, and the in vivo efficacy and immunological profiles were evaluated.
Results: The mean diameter of the nanoglobules ranged from 110 to 148 nm with a polydispersity index of < 1, and the formulation was stable for 3 months at 22 – 28 °C. The LN-model mice that were treated with the nanoemulsion formulation of abatacept showed a marked reduction in immune complexes, improved renal function and decreased ex
Conclusion: The nanoemulsion formulation of abatacept is a promising agent in the treatment of refractory LN. A systematic clinical trial is necessary to establish its long-term efficacy.
Archives
News Updates
Fulltext in PDF